Skip to main content
AUPH
NASDAQ Life Sciences

Aurinia Pharmaceuticals Reports Strong 2025 Results with 25% LUPKYNIS Sales Growth and Positive 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$15
Mkt Cap
$1.902B
52W Low
$6.55
52W High
$16.54
52W Position info
129% above low
Off High info
9.3% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

AUPH has more than doubled off its 52-week low of $6.55.

Summary

Aurinia Pharmaceuticals announced strong financial results for 2025, featuring 25% growth in LUPKYNIS sales, a significant rise in profitability, and positive revenue guidance for 2026.


Key Events · Earnings and Guidance · AUPH

  • Strong LUPKYNIS Sales Growth

    Full-year 2025 LUPKYNIS net product sales increased 25% to $271.3 million, with Q4 sales up 29% to $74.2 million.

  • Significant Profitability Improvement

    Full-year 2025 net income before income taxes rose 1443% to $114.2 million, contributing to diluted earnings per share of $2.07.

  • Positive 2026 Revenue Guidance

    The company expects 2026 total revenue of $315 million to $325 million, representing 11% to 15% growth compared to 2025.

  • Substantial Operating Cash Flow

    Cash flows from operating activities for 2025 increased 206% to $135.7 million, strengthening the company's financial position.


Analysis · AUPH · Life Sciences

Aurinia Pharmaceuticals delivered a robust financial performance for 2025, primarily driven by strong LUPKYNIS net product sales growth of 25% year-over-year. The company achieved a significant increase in net income before income taxes, demonstrating improved operational profitability. While the reported net income and diluted EPS were substantially boosted by a one-time income tax benefit from the release of a valuation allowance on deferred tax assets, the underlying business performance was strong. The positive 2026 revenue guidance, projecting 11% to 15% growth, indicates continued confidence in LUPKYNIS adoption and overall business trajectory. Additionally, the company's share repurchase program in 2025 signals a commitment to returning value to shareholders.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AUPH was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $6.55 to $16.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Oct 30, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.62
Real-time Price: $15.73 info
Change: -$0.890 (-5%) info
Market Cap: $2.108B info
AUPH
Oct 30, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $17.21
Real-time Price: $15.73 info
Change: -$1.48 (-9%) info
Market Cap: $2.108B info
AUPH
Aug 19, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.34
Real-time Price: $15.73 info
Change: -$0.610 (-4%) info
Market Cap: $2.108B info
AUPH
Aug 19, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.57
Real-time Price: $15.73 info
Change: -$0.840 (-5%) info
Market Cap: $2.108B info
AUPH
Aug 06, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $15.73 info
Change: -$0.020 (-0.13%) info
Market Cap: $2.108B info